BNKK
Price
$3.75
Change
+$3.36 (+861.54%)
Updated
Feb 3, 04:59 PM (EDT)
Capitalization
21.3M
22 days until earnings call
Intraday BUY SELL Signals
DVAX
Price
$15.48
Change
+$5.13 (+49.57%)
Updated
Feb 3, 04:59 PM (EDT)
Capitalization
1.76B
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BNKK vs DVAX

Header iconBNKK vs DVAX Comparison
Open Charts BNKK vs DVAXBanner chart's image
Bonk
Price$3.75
Change+$3.36 (+861.54%)
Volume$5.23K
Capitalization21.3M
Dynavax Technologies
Price$15.48
Change+$5.13 (+49.57%)
Volume$40.6K
Capitalization1.76B
BNKK vs DVAX Comparison Chart in %
View a ticker or compare two or three
VS
BNKK vs. DVAX commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNKK is a Hold and DVAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (BNKK: $4.01 vs. DVAX: $15.49)
Brand notoriety: BNKK and DVAX are both not notable
BNKK represents the Investment Managers, while DVAX is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BNKK: 3% vs. DVAX: 24%
Market capitalization -- BNKK: $21.3M vs. DVAX: $1.76B
BNKK [@Investment Managers] is valued at $21.3M. DVAX’s [@Pharmaceuticals: Generic] market capitalization is $1.76B. The market cap for tickers in the [@Investment Managers] industry ranges from $173.66B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.68B to $0. The average market capitalization across the [@Investment Managers] industry is $7.45B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BNKK’s FA Score shows that 0 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).

  • BNKK’s FA Score: 0 green, 5 red.
  • DVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, DVAX is a better buy in the long-term than BNKK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BNKK’s TA Score shows that 6 TA indicator(s) are bullish while DVAX’s TA Score has 4 bullish TA indicator(s).

  • BNKK’s TA Score: 6 bullish, 4 bearish.
  • DVAX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BNKK is a better buy in the short-term than DVAX.

Price Growth

BNKK (@Investment Managers) experienced а -16.80% price change this week, while DVAX (@Pharmaceuticals: Generic) price change was -0.19% for the same time period.

The average weekly price growth across all stocks in the @Investment Managers industry was -2.00%. For the same industry, the average monthly price growth was +6.61%, and the average quarterly price growth was +10.32%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +19.34%. For the same industry, the average monthly price growth was +0.79%, and the average quarterly price growth was +16.45%.

Reported Earning Dates

BNKK is expected to report earnings on Feb 25, 2026.

DVAX is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Investment Managers (-2.00% weekly)

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

@Pharmaceuticals: Generic (+19.34% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DVAX($1.76B) has a higher market cap than BNKK($21.3M). BNKK YTD gains are higher at: 55.426 vs. DVAX (0.715). DVAX has higher annual earnings (EBITDA): -25.65M vs. BNKK (-37.41M). DVAX has more cash in the bank: 648M vs. BNKK (9.12M). BNKK has less debt than DVAX: BNKK (382K) vs DVAX (285M). DVAX has higher revenues than BNKK: DVAX (331M) vs BNKK (2.29M).
BNKKDVAXBNKK / DVAX
Capitalization21.3M1.76B1%
EBITDA-37.41M-25.65M146%
Gain YTD55.4260.7157,750%
P/E RatioN/A54.60-
Revenue2.29M331M1%
Total Cash9.12M648M1%
Total Debt382K285M0%
FUNDAMENTALS RATINGS
DVAX: Fundamental Ratings
DVAX
OUTLOOK RATING
1..100
30
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
PROFIT vs RISK RATING
1..100
55
SMR RATING
1..100
93
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BNKKDVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 7 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 13 days ago
84%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 12 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
BNKK
Daily Signal:
Gain/Loss:
DVAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JUNS0.590.06
+11.78%
Jupiter Neurosciences Inc
CRSP51.311.35
+2.70%
CRISPR Therapeutics AG
RACE336.333.16
+0.95%
Ferrari NV
CDNA20.42-0.13
-0.63%
CareDx
MASS6.19-0.12
-1.90%
908 Devices

BNKK and

Correlation & Price change

A.I.dvisor tells us that BNKK and PBH have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNKK and PBH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNKK
1D Price
Change %
BNKK100%
+4.16%
PBH - BNKK
23%
Poorly correlated
+1.50%
CPIX - BNKK
21%
Poorly correlated
+2.93%
SNDL - BNKK
21%
Poorly correlated
-0.65%
DVAX - BNKK
21%
Poorly correlated
+0.03%
TLRY - BNKK
21%
Poorly correlated
-0.27%
More

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.03%
ACET - DVAX
39%
Loosely correlated
-0.13%
SNDL - DVAX
35%
Loosely correlated
-0.65%
COLL - DVAX
26%
Poorly correlated
+2.59%
AMRX - DVAX
25%
Poorly correlated
+3.73%
HCM - DVAX
24%
Poorly correlated
-2.93%
More